DrugPatentWatch Database Preview
Investigational Drug Information for Delamanid
Email this page to a colleague
What is the drug development status for Delamanid?
Delamanid is an investigational drug.
There have been 19 clinical trials for Delamanid.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2020.
The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Multidrug-Resistant, and Tuberculosis, Pulmonary. The leading clinical trial sponsors are Otsuka Pharmaceutical Development & Commercialization, Inc., National Institute of Allergy and Infectious Diseases (NIAID), and Harvard Medical School.
There are nine US patents protecting this investigational drug and two hundred and eighty-nine international patents.
Summary for Delamanid
| US Patents | 9 |
| International Patents | 289 |
| US Patent Applications | 26 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2020-07-01) |
| Vendors | 45 |
Recent Clinical Trials for Delamanid
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB | De La Salle Health Sciences Institute, Philippines | Phase 2 |
| Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB | Harvard Medical School | Phase 2 |
| Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB | Harvard Medical School (HMS and HSDM) | Phase 2 |
Clinical Trial Summary for Delamanid
Top disease conditions for Delamanid
Top clinical trial sponsors for Delamanid
US Patents for Delamanid
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Delamanid | ⤷ Try it Free | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | Global Alliance for TB Drug Development (New York, NY) | ⤷ Try it Free |
| Delamanid | ⤷ Try it Free | Pharmaceutical composition achieving excellent absorbency of pharmacologically active substance | Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP) | ⤷ Try it Free |
| Delamanid | ⤷ Try it Free | Antituberculous composition comprising oxazole compounds | Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP) | ⤷ Try it Free |
| Delamanid | ⤷ Try it Free | Nitroimidazooxazines and their uses in anti-tubercular therapy | Global Alliance for TB Drug Development (New York, NY) | ⤷ Try it Free |
| Delamanid | ⤷ Try it Free | Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same | UNIVERSITY OF NOTRE DAME DU LAC (Notre Dame, IN) | ⤷ Try it Free |
| Delamanid | ⤷ Try it Free | Combination therapy to treat Mycobacterium diseases | SPERO TRINEM, INC. (Cambridge, MA) | ⤷ Try it Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Delamanid
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Delamanid | China | CN107406386 | 2035-03-27 | ⤷ Try it Free |
| Delamanid | Eurasian Patent Organization | EA201792154 | 2035-03-27 | ⤷ Try it Free |
| Delamanid | European Patent Office | EP3275862 | 2035-03-27 | ⤷ Try it Free |
| Delamanid | Japan | JP6776226 | 2035-03-27 | ⤷ Try it Free |
| Delamanid | Japan | JPWO2016158737 | 2035-03-27 | ⤷ Try it Free |
| Delamanid | South Korea | KR20170129898 | 2035-03-27 | ⤷ Try it Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
